ArticleVaccines2022

Comparison of the Safety and Immunogenicity of FAKHRAVAC and BBIBP-CorV Vaccines when Administrated as Booster Dose: A Parallel Two Arms, Randomized, Double Blind Clinical Trial.

Mohammadreza Ahi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.